For the year ending 2025-12-31, COEP made $1,363,045 in revenue. -$11,917,015 in net income. Net profit margin of -874.29%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Total sales | 1,363,045 | |||
| Cost of goods | 180,625 | |||
| Gross profit | 1,182,420 | |||
| Research and development expense | 1,277,150 | |||
| Salary expense | 1,687,972 | |||
| Amortization expense | 1,000,000 | |||
| Professional services expense | 7,792,100 | |||
| Stock based compensation expense | 1,215,692 | |||
| General and administrative expenses | 1,148,004 | |||
| Selling and marketing expense | 105,000 | |||
| Total cost of operations | 14,225,918 | |||
| Loss from operations | -13,043,498 | |||
| Interest expense | 96,744 | |||
| Interest income | 116,495 | |||
| Amortization of debt discount | 545,635 | |||
| Gain on forfeiture of customer deposit | 115,000 | |||
| Other income (expense), net | 7,004 | |||
| Unrealized gain on marketable securities | 76,596 | |||
| Unrealized loss on investments | -163,500 | |||
| Loss on write down of assets | 0 | |||
| Gain (loss) on extinguishment of debt | 159,035 | |||
| Change in fair value of derivative liabilities | 1,098,055 | |||
| Total other income (expense), net | 766,306 | |||
| Loss before income taxes | -12,277,192 | |||
| Provision for income taxes (benefit) | 0 | |||
| Net loss | -12,277,192 | |||
| Net loss attributable to non-controlling interests | -360,177 | |||
| Net loss attributable to common stockholders | -11,917,015 | |||
| Basic EPS | -2.81 | |||
| Diluted EPS | -2.81 | |||
| Basic Average Shares | 4,234,787 | |||
| Diluted Average Shares | 4,234,787 | |||
Coeptis Therapeutics Holdings, Inc. (COEP)
Coeptis Therapeutics Holdings, Inc. (COEP)